Edison Investment Research - Trifast PLC (TRI) Trifast - Project Atlas helps map the future

Report

Edison Investment Research

Andy Chambers

Trifast - Project Atlas helps map the future

Trifast delivered another record financial performance. FY18 results were modestly ahead of market expectations, but significantly ahead of expectations at the start of the year. Management is now launching Project Atlas to integrate its management, customer-facing and manufacturing processes through a Â£15m investment over the next three years. By maintaining leading customer service and quality levels, the move is a clear support for the invest and grow strategy. Following the recent acquisition of Precision Technology Supplies (PTS) in the UK, the company retains adequate resources to pursue additional M&A should appropriate opportunities arise.

22/06/2018 10 EN

Underlying

Trifast PLC

Trifast is engaged in the engineering, manufacturing and distribution of industrial fastenings and category C components to a range of industries and customers. The key end markets in which these products can be found are automotive, electronics and domestic appliances. Co. has a range of self-clinch fastenings, blind rivets and rivet nuts, rivet bushes and thread forming screws. Co. also designs and supplies locking systems and locks, hinges and latches, clamps and terminals, gaskets and accessories. Co. operates in Norway, Sweden, Hungary, Ireland, Holland, Italy, Germany, Spain and Poland; in U.S. and Mexico; and in Malaysia, China, Singapore, Taiwan, Thailand and India.

See profile

GB0008883927 London Stock Exchange United Kingdom

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Andy Chambers

Other Reports on these Companies

SmartInsider

Trifast: 1 director

A director at Trifast bought/maiden bought 40,000 shares at 74p and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of bo...

Free Trial

April 15, 2024 April 15, 2024 1 EN

Zeus Capital

Audio Note: Trifast - Market demand weakens in December

In this audio note, Zeus’ Andy Hanson summarises the investment case for Trifast. Trifast has released a trading update indicating that demand in Asia and global distribution sales channels has been weak in December leading to a decline in volumes. Listen to the audio note below, and read the full research here.

January 29, 2024 January 29, 2024 1 EN

Zeus Capital

Audio Note: Trifast - Interim results show strategic progress

In this audio note, Zeus’ Andy Hanson summarises the investment case for Trifast. Trifast has announced an encouraging set of interim results both operationally and financially. Listen to the audio note below, and read the full research here.

November 23, 2023 November 23, 2023 1 EN

discoverIE Group - FY24 EPS in line; good margin progress

discoverIE anticipates reporting FY24 underlying EPS in line with board expectations. After a period in mid-FY24 of working down inventory, customers appear to be reverting to normal ordering patterns, with Q424 organic revenue growth of 2% y-o-y and 11% q-o-q and a strong pipeline of design wins at year-end. We have revised our forecasts to reflect lower revenue, partly due to a disposal, but maintain our profit forecasts, which results in operating margin expansion in FY24 and FY25.

37m 37m 1 EN

Sean Conroy

Sean Conroy

Ultimovacs - Steadfast commitment to UV1 progression

Despite the recent setback with the INITIUM trial (first-line treatment of patients with unresectable or metastatic malignant melanoma), Ultimovacs has reinstated its commitment to press on with its clinical development of its cancer vaccine, UV1, across other target indications. The principal near-term focus will be on the anticipated results of Phase II FOCUS (head and neck cancer) and DOVACC (ovarian cancer) trials in Q324 and H125, respectively, and will inform its subsequent strategic direction. To remain funded to these milestones, the company has enforced stringent cost control measures...

20h / 40m 20h / 40m 1 EN

Sean Conroy

Sean Conroy

OSE Immunotherapeutics - AbbVie deal clears antitrust hurdle

OSE has announced that its licence agreement with AbbVie has cleared antitrust review and has become effective. As previously noted, this is expected to support OSE’s runway extension into 2026, past key milestones and readouts for in-house assets Tedopi (non-small cell lung cancer, US Phase III trials expected to commence in Q224) and Lusvertikimab (ulcerative colitis, Phase II readouts expected in mid-2024). Following the Federal Communications Commission (FCC) mandatory waiting period, OSE is expected to receive the negotiated US$48m upfront payment from AbbVie imminently, as part of its gl...

20h / 52m 20h / 52m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN